Netarsudil Mesylate Patent Expiration
Netarsudil Mesylate is Used for lowering elevated intraocular pressure. It was first introduced by Alcon Laboratories Inc
Netarsudil Mesylate Patents
Given below is the list of patents protecting Netarsudil Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rhopressa | US10588901 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rhopressa | US11020385 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rhopressa | US11185538 | Compositions for treating glaucoma or reducing intraocular pressure | Mar 14, 2034 | Alcon Labs Inc |
| Rhopressa | US9415043 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rhopressa | US9931336 | Combination therapy | Mar 14, 2034 | Alcon Labs Inc |
| Rhopressa | US8394826 | Dual mechanism inhibitors for the treatment of disease | Nov 10, 2030 | Alcon Labs Inc |
| Rhopressa | US10174017 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rhopressa | US10654844 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rhopressa | US11028081 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rhopressa | US11618748 | Dual mechanism inhibitors for the treatment of disease | Jan 27, 2030 | Alcon Labs Inc |
| Rhopressa | US10532993 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rhopressa | US10882840 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rhopressa | US11021456 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rhopressa | US8450344 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
| Rhopressa | US9096569 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | Jul 11, 2026 | Alcon Labs Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Netarsudil Mesylate's patents.
Latest Legal Activities on Netarsudil Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Netarsudil Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10882840 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US8394826 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US9415043 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US10174017 |
| Correspondence Address Change Critical | 25 Mar, 2024 | US8450344 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US10588901 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US11028081 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US11021456 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US10532993 |
| Correspondence Address Change Critical | 20 Mar, 2024 | US10654844 |
Netarsudil Mesylate's Family Patents
